The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on ...

Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara ...